X marks the shot against malaria

Raphael A. Reyes; Rolando Garza; Evelien M. Bunnik

doi:10.1016/j.immuni.2023.01.018

X marks the shot against malaria

Raphael A. Reyes, Rolando Garza, Evelien M. Bunnik

Department of Microbiology, Immunology & Molecular Genetics

Producción científica: Comment/debate › revisión exhaustiva

Resumen

The development of a transmission-blocking vaccine (TBV) against malaria is hampered by poor understanding of functional antibody responses. In this issue of Immunity, Fabra-Garcia et al., Ivanochko et al., and Tang et al. isolate human monoclonal antibodies against the two most promising TBV candidates, Pfs48/45 and Pfs230, and map the epitopes responsible for potent transmission-reducing activity.

Idioma original	English (US)
Páginas (desde-hasta)	234-236
Número de páginas	3
Publicación	Immunity
Volumen	56
N.º	2
DOI	https://doi.org/10.1016/j.immuni.2023.01.018
Estado	Published - feb 14 2023

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

Acceder al documento

10.1016/j.immuni.2023.01.018

Otros archivos y enlaces

Citar esto

@article{5f74a72642174f0ab771a3a1ca5b174a,

title = "X marks the shot against malaria",

abstract = "The development of a transmission-blocking vaccine (TBV) against malaria is hampered by poor understanding of functional antibody responses. In this issue of Immunity, Fabra-Garcia et al., Ivanochko et al., and Tang et al. isolate human monoclonal antibodies against the two most promising TBV candidates, Pfs48/45 and Pfs230, and map the epitopes responsible for potent transmission-reducing activity.",

author = "Reyes, {Raphael A.} and Rolando Garza and Bunnik, {Evelien M.}",

note = "Funding Information: Work in the Bunnik Lab is supported by the NIH ( R01 AI153425 to E.M.B. and F31 AI169993 to R.A.R.). We thank Sebastiaan Bol for editing and critical discussions about the contents of this Preview. We also thank Emma Vidal from DrawImpacts for drawing the figure. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = feb,

day = "14",

doi = "10.1016/j.immuni.2023.01.018",

language = "English (US)",

volume = "56",

pages = "234--236",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - X marks the shot against malaria

AU - Reyes, Raphael A.

AU - Garza, Rolando

AU - Bunnik, Evelien M.

N1 - Funding Information: Work in the Bunnik Lab is supported by the NIH ( R01 AI153425 to E.M.B. and F31 AI169993 to R.A.R.). We thank Sebastiaan Bol for editing and critical discussions about the contents of this Preview. We also thank Emma Vidal from DrawImpacts for drawing the figure. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/2/14

Y1 - 2023/2/14

N2 - The development of a transmission-blocking vaccine (TBV) against malaria is hampered by poor understanding of functional antibody responses. In this issue of Immunity, Fabra-Garcia et al., Ivanochko et al., and Tang et al. isolate human monoclonal antibodies against the two most promising TBV candidates, Pfs48/45 and Pfs230, and map the epitopes responsible for potent transmission-reducing activity.

AB - The development of a transmission-blocking vaccine (TBV) against malaria is hampered by poor understanding of functional antibody responses. In this issue of Immunity, Fabra-Garcia et al., Ivanochko et al., and Tang et al. isolate human monoclonal antibodies against the two most promising TBV candidates, Pfs48/45 and Pfs230, and map the epitopes responsible for potent transmission-reducing activity.

UR - http://www.scopus.com/inward/record.url?scp=85147676339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147676339&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2023.01.018

DO - 10.1016/j.immuni.2023.01.018

M3 - Comment/debate

C2 - 36792569

AN - SCOPUS:85147676339

SN - 1074-7613

VL - 56

SP - 234

EP - 236

JO - Immunity

JF - Immunity

IS - 2

ER -

X marks the shot against malaria

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto